A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain

Aaron Yarlas, Kate Miller, Warren Wen, Bradley Dain, Shau Yu Lynch, Joseph V. Pergolizzi, Robert B. Raffa, Steven R. Ripa

Research output: Contribution to journalArticle

Abstract

This study evaluated the impact of treatment with Buprenorphine Transdermal System (BTDS) on the health-related quality of life for patients with moderate-to-severe chronic low back pain (CLBP), and the correspondence between quality of life and pain. A multicenter, enriched, double-blind (DB), placebo-controlled, randomized trial evaluated BTDS 10 and 20 μg/hour for treatment of opioid-naïve patients with moderate-to-severe CLBP. The SF-36v2 survey, which measures 8 domains of quality of life, was administered at screening and following an open-label run-in period with BTDS and at weeks 4, 8, and 12 of the DB phase. Post hoc analyses compared SF-36v2 scores between BTDS and placebo groups during the DB phase. Condition burden was examined through comparisons with a U.S. general population sample. Correlations examined the correspondence between quality of life and pain measures. BTDS produced larger improvements than placebo at 12 weeks in all quality-of-life domains (Ps

Original languageEnglish (US)
Pages (from-to)14-23
Number of pages10
JournalJournal of Pain
Volume14
Issue number1
DOIs
StatePublished - Jan 2013

    Fingerprint

Keywords

  • Buprenorphine
  • health-related quality of life
  • low back pain
  • opioid treatment
  • transdermal delivery

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neurology
  • Clinical Neurology

Cite this